Second, while autologous NK cells are inherently HLA-matched and theoretically reduce graft rejection risks, their utility is often compromised by functional exhaustion, tumor-induced immunosuppression (e.g., downregulated NKG2D),62 and prolonged manufacturing timelines, particularly in patients with advanced malignancies. This evidence concerns the gene KLRK1 and neoplasm.